Simvastatin in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Using Avonex Compared to Placebo

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00668343

Acronym

irmsrct

Enrollment

Registered

2008-04-29

Start date

2005-04-30

Completion date

2009-03-31

Last updated

2010-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsing Remitting Multiple Sclerosis

Keywords

edss attack

Brief summary

Patient with relapsing remitting multiple sclerosis taking avonex are included in this double blind randomized control trial. Simvastatin is compared to placebo. end points of edss , total attack, new enhancing lesion and newt2 lesion in mri is evaluated as end point.

Interventions

DRUGsimvastatin

40 mg/ day

DRUGplacebo

80 mg /day

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

15 Years to 60 Years

Healthy volunteers

Inclusion criteria

1. edss\<5 2. \>=1 attack in last year

Exclusion criteria

1. \>2 attacks in study 2. drug complication

Design outcomes

Primary

Measure	Time frame
attack number	1 year

Countries

Iran

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 31, 2026